Dabrafenib is a selective BRAF kinase inhibitor used in the treatment of BRAF V600 mutation-positive cancers, including melanoma and non-small cell lung cancer. It inhibits mutant BRAF kinase activity, reducing tumor cell proliferation and survival. Dabrafenib API is produced under stringent quality standards and is suitable for oral solid dosage forms, such as capsules.

Dabrafenib API is manufactured and supplied by ASTANDARDS | Artis Biotech, ensuring high purity, consistent quality, and regulatory-compliant specifications. Our APIs are produced using validated processes and are suitable for research, development, and pharmaceutical manufacturing applications.